OncoMatch/Clinical Trials/NCT06343064
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
Is NCT06343064 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Vebreltinib and PLB1004 for non-small-cell lung cancer.
Treatment: Vebreltinib · PLB1004 — Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
EGFR mutations, including exon 19 deletion and exon 21 L858R
Required: EGFR L858R
EGFR mutations, including exon 19 deletion and exon 21 L858R
Required: MET overexpression
C-Met overexpression and/or c-Met amplification confirmed after treatment with EGFR-TKI
Required: MET amplification
C-Met overexpression and/or c-Met amplification confirmed after treatment with EGFR-TKI
Excluded: ALK mutation
There are mutations of ALK
Excluded: ROS1 mutation
There are mutations of ... ROS1
Disease stage
Required: Stage IIIB, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor
C-Met overexpression and/or c-Met amplification confirmed after treatment with EGFR-TKI
Cannot have received: MET inhibitor
Previous treatment with MET inhibitors
Cannot have received: HGF-targeted therapy
Previous treatment with ... HGF-targeted therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06343064 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MET inhibitor, HGF-targeted therapy disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR exon 19 deletion is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR L858R is a required biomarker for enrollment.
Does this trial require MET?
Yes, MET overexpression is a required biomarker for enrollment.
Are patients with ALK alterations eligible?
No. ALK mutation is an exclusion criterion.
Are patients with ROS1 alterations eligible?
No. ROS1 mutation is an exclusion criterion.
What disease stage is eligible?
Stage IIIB or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify